8-K: Celularity Secures $6.67M High-Cost Private Placement

Celularity Inc. has entered into a private placement agreement to raise up to $6.67 million through the issuance of Series A Convertible Preferred Stock and warrants, with an initial $2 million tranche closing immediately.

Summary

• Celularity Inc. has entered into a Securities Purchase Agreement with an institutional investor for a private placement of up to $6,666,667 in stated value of Series A Convertible Preferred Stock and accompanying warrants.
• The Preferred Stock is purchased at 90% of its stated value, with each share having a stated value of $1.111111, and warrants are issued for no additional consideration with an initial exercise price of $3.00 per share.
• The transaction is structured in up to three tranches, with the initial $2,000,000 tranche closing on October 24, 2025, and proceeds intended for working capital and general corporate purposes.
• Series A Preferred Stock carries a 5.0% annual dividend, increasing to 18.0% per annum during a 'Triggering Event', payable quarterly in cash or as payment-in-kind (PIK).
• Conversion of Preferred Stock and exercise of warrants are subject to beneficial ownership limitations (initially 4.99%, adjustable to 19.99%) and an Exchange Cap of 19.99% of outstanding Common Stock, requiring stockholder approval for amounts exceeding this cap.
• A Registration Rights Agreement mandates filing a resale registration statement within 30 days and using best efforts for effectiveness within 90 days.
• A Security Agreement grants the investor a first priority security interest in certain company assets, and an Exchange Promissory Note (18.0% annual interest) can be issued upon a Triggering Event, allowing exchange of up to $2,000,000 in Preferred Shares.

Sentiment

Score: 3

Explanation: The capital raise provides necessary funding, but the terms (high dividend/interest rates, security interest, significant dilution potential, and numerous default triggers) are highly unfavorable to existing common shareholders and suggest underlying financial distress or high perceived risk for the company. While capital is secured, the cost is substantial and could burden future financial performance.

Positives

• Secures up to $6,666,667 in capital, providing funds for working capital and general corporate purposes.
• The initial tranche of $2,000,000 has already closed, providing immediate capital.
• The structure allows for additional capital raises in subsequent tranches, subject to certain conditions.
• The investor has a 'Most Favored Nation' clause, ensuring they receive terms as favorable as any future investors.
• The investor has a right to participate in up to 20% of any future equity financing.

Negatives

• The Series A Preferred Stock is convertible at a price that can be as low as 95% of the lowest VWAP over seven trading days, potentially leading to significant dilution for existing common stockholders.
• The dividend rate on the Preferred Stock is 5.0% per annum, increasing to 18.0% during a 'Triggering Event,' which is a high cost of capital, especially under adverse conditions.
• The issuance of shares upon conversion/exercise is subject to an Exchange Cap of 19.99% of outstanding Common Stock, requiring stockholder approval for further issuances, which could delay or limit full conversion.
• The Exchange Promissory Note carries an 18.0% interest rate, and a 10% prepayment premium, indicating a high cost of debt if triggered.
• The company granted a first priority security interest in certain assets, which could limit future financing options or impact existing creditors.
• The investor has significant protective provisions, including anti-dilution adjustments and remedies upon various 'Triggering Events' or 'Events of Default,' which could be onerous for the company.

Risks

• Dilution Risk: Conversion of Preferred Stock and exercise of Warrants at potentially low prices could significantly dilute existing common stockholders.
• High Cost of Capital: The 5.0% dividend rate on Preferred Stock (18.0% during Triggering Event) and 18.0% interest rate on the Exchange Promissory Note represent a substantial cost of capital.
• Shareholder Approval Risk: The Exchange Cap requires stockholder approval for issuances exceeding 19.99% of outstanding Common Stock, and failure to obtain this could limit the company's ability to fully convert the securities.
• Default Risk: Numerous 'Triggering Events' and 'Events of Default' (e.g., failure to meet reporting requirements, trading suspension, judgments >$250k, material breach of covenants) could lead to accelerated obligations, higher interest rates, or mandatory redemptions.
• Liquidity Risk: Failure to deliver Conversion Shares on time incurs liquidated damages ($10-$20 per $1,000 of shares per Trading Day), potentially straining liquidity.
• Security Interest: Granting a first priority security interest in assets could complicate future financing or asset sales.
• Market Price Volatility: The conversion price and warrant exercise price are tied to VWAP, making the number of shares issued dependent on stock performance, which can be volatile.
• Regulatory Compliance Risk: Failure to comply with NASDAQ rules (e.g., Rule 5635 for stockholder approval) could lead to delisting or other penalties.

Future Outlook

The company intends to use the net proceeds from the private placement for working capital and general corporate purposes, indicating a focus on sustaining current operations and potentially future growth initiatives. The structure of the tranches suggests a phased approach to capital deployment, with subsequent tranches contingent on certain conditions, including the effectiveness of a resale registration statement.

Management Comments

• The Company intends to use the net proceeds received from the Private Placement for working capital and general corporate purposes.

Industry Context

This private placement provides capital to Celularity, a biotechnology company, which is common in the capital-intensive biotech industry where companies often require significant funding for research, development, and operational expenses before achieving profitability. The high dividend and interest rates, along with the security interest, suggest the company may be facing challenges in securing less dilutive or cheaper financing, or that the investor perceives a higher risk profile. The need for stockholder approval for exceeding the 19.99% Exchange Cap is a standard NASDAQ requirement for dilutive issuances, reflecting regulatory oversight in public markets.

Comparison to Industry Standards

• The 5.0% dividend rate on preferred stock, escalating to 18.0% during a Triggering Event, and the 18.0% interest rate on the Exchange Promissory Note are significantly higher than typical rates for established, profitable companies. These rates are more comparable to distressed debt or highly speculative venture capital financing, suggesting a higher perceived risk by the institutional investor.
• The beneficial ownership limitation (4.99%, adjustable to 19.99%) and the Exchange Cap (19.99% requiring shareholder approval) are standard protective provisions often seen in private placements for public companies to manage dilution and comply with exchange rules (e.g., NASDAQ Rule 5635), similar to agreements seen with companies like Sorrento Therapeutics or other small-cap biotech firms seeking capital.
• The granting of a first priority security interest in certain assets is a strong protective measure for the investor, typically seen in situations where the company's creditworthiness is a concern or where the investor demands enhanced security, akin to debt financing terms rather than pure equity investment.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Potential for significant dilution due to the conversion terms of the Preferred Stock and Warrants, especially if the stock price declines. The high cost of capital (dividends, interest) will impact future earnings available to common shareholders. The first priority security interest granted to the investor could also negatively impact common shareholders in a liquidation scenario.
• Investors (Institutional Investor): Benefits from strong protective provisions, including high dividend/interest rates, anti-dilution adjustments, a first priority security interest, and the ability to convert to a high-interest promissory note upon triggering events. This structure provides significant downside protection and potential for substantial returns.
• Company Management: Gains access to capital for working capital and general corporate purposes, which is crucial for operations. However, they must manage the complex terms of the agreement, including compliance with conversion limitations, registration requirements, and avoiding triggering events that would increase costs or accelerate obligations.
• Creditors: The granting of a first priority security interest to the institutional investor could subordinate other unsecured creditors in the event of financial distress.

Next Steps

• Company to file a registration statement with the SEC for the resale of the shares underlying the Series A Preferred Stock and Warrants within 30 days of October 24, 2025.
• Company to use reasonable best efforts to have the registration statement declared effective within 90 days of October 24, 2025.
• Company to seek stockholder approval for the issuance of shares exceeding the 19.99% Exchange Cap, as required by NASDAQ rules, no later than 90 days after October 24, 2025.
• Potential closing of a Second Tranche of $2,000,000, subject to the effectiveness of the resale Registration Statement for the Initial Tranche securities and other conditions.
• Potential closing of a Third Tranche of $2,000,000, at the investor's option, within 120 days after the Initial Tranche Closing.
• Company to use net proceeds for working capital and general corporate purposes.

Key Dates

Recommendation

While the capital raise provides much-needed liquidity for Celularity, the terms of the private placement are highly unfavorable and indicative of significant financial distress or a very high-risk profile. The Series A Convertible Preferred Stock carries a 5.0% dividend, escalating to 18.0% upon a Triggering Event, and the Exchange Promissory Note has an 18.0% interest rate. These are exceptionally high costs of capital. Furthermore, the investor receives a first priority security interest in company assets, which is a strong protective measure for them but significantly disadvantages other creditors and common shareholders in a downside scenario. The potential for substantial dilution from the conversion of preferred stock and warrants, coupled with the numerous and broad 'Triggering Events' and 'Events of Default' that can accelerate obligations or increase costs, places considerable future burden on the company. The requirement for stockholder approval for issuances exceeding the 19.99% Exchange Cap highlights the dilutive nature of the transaction. For a seasoned investor, these terms suggest that the company is in a precarious position, and the long-term value for common shareholders is likely to be severely eroded by the cost and structure of this financing. The immediate capital infusion is a short-term positive, but the long-term implications are overwhelmingly negative, warranting a 'sell' recommendation.

Keywords

Celularity Inc., Private Placement, Series A Convertible Preferred Stock, Warrants, SEC Filing, 8-K, Capital Raise, Dilution, Corporate Finance, NASDAQ, Stockholder Approval, Convertible Securities, Financial Health, Risk Management, CELU